{
    "id": 3130,
    "fullName": "ALK F1174I",
    "impact": "missense",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "ALK F1174I lies within the protein kinase domain of the Alk protein (UniProt.org). F1174I results in ligand-independent phosphorylation of the Alk protein, activation of Erk, Stat3 pathways, and is transforming in cell culture (PMID: 23104988).",
            "references": [
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                },
                {
                    "id": 1899,
                    "pubMedId": 23104988,
                    "title": "Cell culture and Drosophila model systems define three classes of anaplastic lymphoma kinase mutations in neuroblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23104988"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 238,
        "geneSymbol": "ALK",
        "terms": [
            "ALK",
            "CD246",
            "NBLST3"
        ]
    },
    "variant": "F1174I",
    "createDate": "02/16/2015",
    "updateDate": "09/06/2018",
    "referenceTranscriptCoordinates": {
        "id": 102020,
        "transcript": "NM_004304",
        "gDna": "chr2:g.29220831A>T",
        "cDna": "c.3520T>A",
        "protein": "p.F1174I",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 5392,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, human anaplastic large cell lymphoma cell lines harboring NPM1-ALK with ALK with ALK F1174I were resistant to ASP3026 mediated growth inhibition in culture (PMID: 25749034).",
            "molecularProfile": {
                "id": 20772,
                "profileName": "NPM1 - ALK ALK F1174I"
            },
            "therapy": {
                "id": 643,
                "therapyName": "ASP3026",
                "synonyms": null
            },
            "indication": {
                "id": 50744,
                "name": "anaplastic large cell lymphoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 5029,
                    "pubMedId": 25749034,
                    "title": "NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25749034"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5493,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Lorlatinib (PF-06463922) inhibited growth of transformed cells expressing NPM1-ALK with ALK F1174I in culture (PMID: 25749034).",
            "molecularProfile": {
                "id": 20772,
                "profileName": "NPM1 - ALK ALK F1174I"
            },
            "therapy": {
                "id": 869,
                "therapyName": "Lorlatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5029,
                    "pubMedId": 25749034,
                    "title": "NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25749034"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5435,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Alunbrig (brigatinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK F1174I in culture (PMID: 25749034).",
            "molecularProfile": {
                "id": 20772,
                "profileName": "NPM1 - ALK ALK F1174I"
            },
            "therapy": {
                "id": 634,
                "therapyName": "Brigatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5029,
                    "pubMedId": 25749034,
                    "title": "NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25749034"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5484,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Zykadia (ceritinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK F1174I in culture (PMID: 25749034).",
            "molecularProfile": {
                "id": 20772,
                "profileName": "NPM1 - ALK ALK F1174I"
            },
            "therapy": {
                "id": 789,
                "therapyName": "Ceritinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5029,
                    "pubMedId": 25749034,
                    "title": "NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25749034"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5424,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing NPM1-ALK with ALK F1174I were resistant to ASP3026 relative to wild type NPM1-ALK in culture (PMID: 25749034).",
            "molecularProfile": {
                "id": 20772,
                "profileName": "NPM1 - ALK ALK F1174I"
            },
            "therapy": {
                "id": 643,
                "therapyName": "ASP3026",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 5029,
                    "pubMedId": 25749034,
                    "title": "NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25749034"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5433,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Alecensa (alectinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK F1174I in culture (PMID: 25749034).",
            "molecularProfile": {
                "id": 20772,
                "profileName": "NPM1 - ALK ALK F1174I"
            },
            "therapy": {
                "id": 698,
                "therapyName": "Alectinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5029,
                    "pubMedId": 25749034,
                    "title": "NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25749034"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5481,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Xalkori (crizotinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK F1174I in culture (PMID: 25749034).",
            "molecularProfile": {
                "id": 20772,
                "profileName": "NPM1 - ALK ALK F1174I"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5029,
                    "pubMedId": 25749034,
                    "title": "NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25749034"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14065,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, ALK F1174I was identified as a compound mutation in transformed cells expressing ALK C1156Y in the context of EML4-ALK that acquired resistance to Lorlatinib (PF-06463922) in culture (PMID: 29650534).",
            "molecularProfile": {
                "id": 29920,
                "profileName": "EML4 - ALK ALK C1156Y ALK F1174I"
            },
            "therapy": {
                "id": 869,
                "therapyName": "Lorlatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 11440,
                    "pubMedId": 29650534,
                    "title": "Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound ALK Mutations in ALK-Positive Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29650534"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 2954,
            "profileName": "ALK F1174I",
            "profileTreatmentApproaches": [
                {
                    "id": 8257,
                    "name": "ALK Inhibitor",
                    "profileName": "ALK F1174I"
                }
            ]
        },
        {
            "id": 20772,
            "profileName": "NPM1 - ALK ALK F1174I",
            "profileTreatmentApproaches": [
                {
                    "id": 16840,
                    "name": "Lorlatinib",
                    "profileName": "NPM1 - ALK ALK F1174I"
                },
                {
                    "id": 16842,
                    "name": "Alectinib",
                    "profileName": "NPM1 - ALK ALK F1174I"
                },
                {
                    "id": 16841,
                    "name": "Ceritinib",
                    "profileName": "NPM1 - ALK ALK F1174I"
                },
                {
                    "id": 16843,
                    "name": "Crizotinib",
                    "profileName": "NPM1 - ALK ALK F1174I"
                },
                {
                    "id": 16844,
                    "name": "Brigatinib",
                    "profileName": "NPM1 - ALK ALK F1174I"
                }
            ]
        },
        {
            "id": 29920,
            "profileName": "EML4 - ALK ALK C1156Y ALK F1174I",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 102020,
            "transcript": "NM_004304",
            "gDna": "chr2:g.29220831A>T",
            "cDna": "c.3520T>A",
            "protein": "p.F1174I",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}